GIIS026-Oncología médica «Miguel Servet»

Hammel P, Metges J, Macarulla Mercade T, Garcia-Carbonero R, Bouché O, Portales F, Pazo Cid R, Mineur L, Cubillo Gracian A, Trouilloud I, Guimbaud R, Tougeron D, Reina J, Feliu J, Sauri T, Fountzilas C, Lecomte T, Molin Y, Ponz-Sarvise M, Forget F, Berardi R, Van Cutsem E, Gelsomino F, Tournigand C, Bockorny B, Bachet J, Marin Vera M, Cuyle P, Wasan H, Noel M, Van Laethem J, Kay R, Youssoufian H, El-Hariry I, Hidalgo M. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreatic Adenocarcinoma. JOURNAL OF CLINICAL ONCOLOGY. 10.1200/JCO-25-00872. Q-1. F.I-41,9

Llombart-Cussac A, Harper-Wynne C, Perello A, Hennequin A, Fernandez-Ortega A, Colleoni M, Marin S, Quiroga V, Medioni J, Iranzo V, Wheatley D, del Barco Berron S, Antón Torres A, Dobi E, Ruiz-Borrego M, Alcala-Lopez D, Perez-Escuredo J, Antonarelli G, Sampayo-Cordero M, Perez-Garcia J, Cortes J. Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial JOURNAL OF CLINICAL ONCOLOGY. 10.1200/JCO-24-01865. Q-1. F.I-41,9

Pascual J, Gil-Gil M, Proszek P, Zielinski C, Reay A, Ruiz-Borrego M, Cutts R, Ciruelos Gil E, Feber A, Muñoz-Mateu M, Swift C, Bermejo B, Herranz J, Margeli Vila M, Antón Torres A, Kahan Z, Csöszi T, Liu Y, Fernandez-Garcia D, Garcia-Murillas I, Hubank M, Turner N, Martín M. Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients. CLINICAL CANCER RESEARCH. 10.1158/1078-0432.CCR-23-0956. Q-1. F.I-10,2

Guerrero-Zotano Á, Belli S, Zielinski C, Gil-Gil M, Fernandez-Serra A, Ruiz-Borrego M, Ciruelos Gil E, Pascual J, Muñoz-Mateu M, Bermejo B, Margeli Vila M, Antón Torres A, Murillo Jaso L, Nissenbaum B, Liu Y, Herranz J, Fernández-García D, Caballero R, López-Guerrero J, Bianco R, Formisano L, Turner N, Martín M. CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2- Metastatic Breast Cancer. CLINICAL CANCER RESEARCH. 10.1158/1078-0432.CCR-22-2206. Q-1. F.I-10,2

André T, Berton D, Curigliano G, Sabatier R, Tinker A, Oaknin A, Ellard S, de Braud F, Arkenau H, Trigo J, Gravina A, Kristeleit R, Moreno V, Abdeddaim C, Vano Y, Samouëlian V, Miller R, Boni V, Antón Torres A, Gilbert L, Brown J, Dewal N, Dabrowski C, Antony G, Zografos E, Veneris J, Banerjee S. Antitumor Activity and Safety of Dostarlimab Monotherapy in Patients With Mismatch Repair Deficient Solid Tumors: A Nonrandomized Controlled Trial. JAMA Network Open. 10.1001/jamanetworkopen.2023.41165. Q-1. F.I-9,7

Martelli V, Vidal J, Gibert J, Fernandez-Rodriguez M, Linares J, Garcia-Alfonso P, Paez D, Alonso Orduña V, Gomez-Espana M, Guix M, Santos C, Duran G, Elez E, Garcia-Carbonero R, Ferreiro R, Pineda E, Sastre J, Cano M, Manzano J, Losa F, Aranda E, Rivera F, Sibilio A, Toledo R, Tabernero J, Salazar R, Bellosillo B, Montagut C, Spanish Cooperative Grp Treatment Digestive Tumours TTD . Clinical validation of liquid biopsy-RECIST (LB-RECIST) in metastatic colorectal cancer (mCRC) patients: findings from the PLATFORM-B study ESMO Open. 10.1016/j.esmoop.2025.105760. Q-1. F.I-8,3

Llombart-Cussac A, Perez-Garcia J, Bellet M, Dalenc F, Gil-Gil M, Ruiz-Borrego M, Gavila J, Schmid P, Zamora P, Wheatley D, Martinez-de Duenas E, Amillano K, Di Cosimo S, Antón Torres A, Cottu P, Shimizu E, Fernandez M, Sampayo-Cordero M, Cortes J, PARSIFAL LONG Steering Committee & Trial Investigators . Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial ESMO Open. 10.1016/j.esmoop.2025.105309. Q-1. F.I-8,3

Wuerstlein R, Ellis P, Montemurro F, Antón Torres A, Delaloge S, Zhang Q, Wang X, Wang S, Shao Z, Li H, Rachman A, Vongsaisuwon M, Liu H, Fear S, Peña-Murillo C, Barrios C. Final results of the global and Asia cohorts of KAMILLA, a phase IIIB safety  trial of trastuzumab emtansine in patients with HER2-positive advanced breast  cancer. ESMO Open. 10.1016/j.esmoop.2022.100561. Q-1. F.I-8,3 Balko J, Licata L, Wang X, Dugo M, Huang C, Egle D, Bermejo B, Zamagni C, Thill M, Antón Torres A, Russo S, Sevillano E, Ciruelos E, Greil R, Semiglazov V, Colleoni M, Kelly C, Mariani G, Del Mastro L, Zambelli S, Viale G, Callari M, Viale G, Pusztai L, Gianni L, Ali H, Bianchini G. Tumor-specific major histocompatibility-II expression predicts pathological complete response to atezolizumab combined to chemotherapy in triple-negative breast cancer npj Breast Cancer. 10.1038/s41523-025-00828-6. Q-1. F.I-7,6

Peña-Enríquez R, Bermejo B, Pollán M, Díaz-Chacón A, Jerez Gilarranz Y, Ponce Lorenzo J, Fernández Aramburo A, Cantos Sánchez de Ibargüen B, Santaballa Bertrán A, Galve-Calvo E, Jiménez-Arranz Á, Fernández Y, Pérez M, De La Cruz S, Antón Torres A, Moreno F, Vidal-Losada M, López-Ceballos M, Blancas I, Echarri M, Rincón R, Caballero R, Guerrero-Zotano Á, Guil-Luna S, de la Haba-Rodríguez J. Molecular characterization of pregnancy-associated breast cancer and insights on timing from GEICAM-EMBARCAM study. npj Breast Cancer. 10.1038/s41523-025-00718-x. Q-1. F.I-7,6